Laura Deming

Laura Deming, the founder of The Longevity Fund and a venture capitalist in anti-aging technology, discusses transformative ideas around human longevity. She explores how we might manipulate aging in humans, not just accept decline as inevitable. Laura highlights a recent breakthrough in lifespan extension for dogs and emphasizes a social approach to the challenge of aging. She advocates for agency over our health choices and envisions a world where extended lifespans allow us to remain active and engaged well into our later years.

with @LauraDeming, @kpfortney, @vijaypande, and @omnivorousread Welcome to the first episode of Bio Eats World, a brand new podcast all about how biology is technology. Bio is breaking out of the lab and clinic and into our daily lives—on the verge of revolutionizing our world in ways we are only just beginning to imagine. In this episode, we talk all about the science of aging. Once a fringe field, aging research is now entering a new phase with the first clinical trials of aging-related drugs. As the entire field shifts into this moment of translation, what have we learned? What are the basic approaches to developing aging-related drugs? How is studying aging helping us understand diseases like cancer and Alzheimer's—and increasing the amount of time we are healthy—today?  In this conversation, Laura Deming, founder of The Longevity Fund; Kristen Fortney, co-founder of BioAge, a clinical-stage company focused on finding drugs to extend healthspan; Vijay Pande, general partner at a16z; and host Hanne Winarsky discuss the entire arc of aging science from one genetic tweak in a tiny worm to changing a whole paradigm of healthcare delivery.

In this podcast, Laura Deming discusses challenging conventional beliefs on aging and healthspan, exploring implications of longer lives and agency over lifespan. The conversation delves into advancing medical research, strategies to extend lifespan in mice, and the potential impact on human health. A fascinating look at the science that could keep us healthy in our 80s and beyond.

Laura Deming, a visionary technologist and venture capitalist, is on a mission to revolutionize longevity. She discusses the philosophical implications of personal identity in the context of anti-aging and cryopreservation. Deming explores what a ‘humane transhumanism’ could look like and highlights the power of scientific awe in sparking innovation. Insights into mentorship in science showcase its impact on aspiring researchers. Lastly, she dives deep into the potential of reversible cryopreservation as a groundbreaking solution for aging and terminal illnesses.

Laura Deming, a General Partner at Longevity Fund, and Will Eden from Sylvan Consulting delve into the fascinating world of biotech investments. They explore the evolution of longevity research and groundbreaking technologies like cell and gene therapies. The duo discusses the FDA's complex role in regulating innovations and the challenges faced by biotech startups. They also highlight the dramatic growth in the longevity sector since 2011 and ponder bold aspirations like biological immortality, making the conversation both insightful and entertaining.